Need For Long-Term CV Studies Goes Beyond COX-2s – Celebrex Study Authors
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory authorities should request long-term cardiovascular safety studies for any new drug that may be used in high-risk patients in light of the COX-2 safety signals, authors of aCelebrex study state
You may also be interested in...
Merck Mulls Possible Vioxx Reintroduction
Merck may reconsider its decision to withdraw the COX-2 inhibitor Vioxx in light of a conclusion by some members of an FDA advisory committee that the cardiovascular signal seen with rofecoxib is a class effect
Merck Mulls Possible Vioxx Reintroduction
Merck may reconsider its decision to withdraw the COX-2 inhibitor Vioxx in light of a conclusion by some members of an FDA advisory committee that the cardiovascular signal seen with rofecoxib is a class effect
COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.